Trials
2 active
17 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Participants will take 5.6 mg of TNX-102 SL ( 2 x 2.8 mg TNX-102 SL tablets) daily at bedtime.”In the company’s words, NCT07621237 on ClinicalTrials.gov
- Tested for
- Major Depressive Episode (MDE), Major Depressive Disorder (MDD), Depression, Pharmakokinetic, Open Label, Phase 1
- Main trialPhase 2
- “The goal of this clinical trial is to learn if a drug called TNX-102 SL works to treat moderate to severe major depressive disorder in adults. It will also learn about the safety of TNX-102 SL. The main questions it aims to answer are: Does TNX-102 SL improve depression symptoms according to a depression symptom rating scale? What medical problems do participants have when taking TNX-102 SL? Researchers will compare TNX-102 SL to a placebo (a look-alike substance that contains no drug) to see if TNX-102 SL works to treat major depressive disorder. Participants will: Take TNX-102 SL or a…”In the company’s words, NCT07621237 on ClinicalTrials.gov
- Other names
- cyclobenzaprine · cyclobenzaprine HCl · cyclobenzaprine HCI
Other drugs for Major Depressive Disorder (MDD)
- SeltorexantJohnson & Johnson (Janssen) · Phase 3
- AzetukalnerXenon Pharmaceuticals Inc. · Phase 3
- LumateperoneIntra-Cellular Therapies, Inc. · Phase 3
- CYB003Cybin IRL Limited · Phase 3
- Mitizodone PhosphateSunshine Lake Pharma Co., Ltd. · Phase 2/3
- OsavampatorNeurocrine Biosciences · Phase 3
Coming up1
- Feb 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials17
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Feb 2028 | A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD) | |
| Phase 1Active, not recruiting | 10 Feb 2026 | A Phase 1, Open-Label, Parallel-Group, Single-Dose Study To Compare The Pharmakokinetics Of TNX-102 SL (Cyclobenzaprine Hydrochloride Sublingual Tablet) In Non-Elderly Versus Elderly Participants | |
| Phase 3Terminated | 13 Sep 2016 | Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia | |
| Phase 3Completed | 28 Sep 2016 | A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients | |
| Phase 3Completed | Sep 2016 | A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia | |
| Phase 3Terminated | 27 Jul 2018 | 12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients | |
| Phase 3Terminated | 27 Jul 2018 | Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSD | |
| Phase 3Completed | 30 Sep 2019 | A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD | |
| Phase 3Terminated | 24 Apr 2020 | A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD | |
| Phase 3Completed | 29 Oct 2020 | A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia | |
| Phase 3Completed | 1 Nov 2021 | A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia | |
| Phase 3Completed | 14 Nov 2023 | A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia | |
| Phase 2Completed | 26 May 2016 | Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related Conditions | |
| Phase 2Completed | May 2016 | Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions | |
| Phase 2Withdrawn | 8 Nov 2022 | Safety and Efficacy Study of TNX-102 SL in Participants With PTSD | |
| Phase 2Completed | 12 Jul 2023 | A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection | |
| Phase 1Completed | 30 Apr 2022 | A Single-Dose, Randomized, Open-Label, 2-Way Crossover Study to Evaluate the Dose-Proportionality, Safety, and Tolerability of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) in Healthy Japanese and Chinese Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026